Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alcon AG (ALC) vs Fabrinet (FN) Price & Performance

Alcon AG
Fabrinet

Price performance

Price movement over the last 24 hours

Key statistics

Alcon AG vs Fabrinet — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Fabrinet trades at $481.14 (market cap $16.79B). The key difference: Alcon AG is the larger of the two by market cap, and Alcon AG pays a 0.54% dividend while Fabrinet pays none. Which is the better fit depends on your goals.

ALCFN
Market Cap
$32.69B$16.79B
Sector
HealthTechnology
52-Week High
$92.22$746.47
52-Week Low
$62.02$277.04
Enterprise Value
$36.28B$15.84B
Dividend Yield
0.54%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alcon AG

ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.

The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.

Fabrinet

FN trades at $500.75, up 0.23% with a bearish technical signal despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters with Q1 2026 EPS of $3.72 exceeding expectations. Analyst consensus remains strongly bullish with 75% buy ratings and a $733 price target, representing 46% upside potential from current levels. Recent news highlights FN's strategic position in AI optical supply chain with capacity expansion supporting multi-year growth visibility.

The outlook remains positive driven by AI infrastructure demand and strong execution, though premium valuation metrics (P/E 43.02) and technical bearish signals warrant caution. Key risks include datacom supply constraints and FX volatility, but robust revenue growth projections ($4.2B for 2026) and expanding margins support the bullish analyst stance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alcon AG

Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.

Read more on ALC

About Fabrinet

Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.

Read more on FN